Beetroot has gained attention as a potential natural remedy for fatty liver disease, with claims circulating about its ability to reverse hepatic steatosis. Whilst this vibrant root vegetable contains beneficial compounds including betaine, betalains, and dietary nitrates, the evidence for its therapeutic effect on fatty liver remains limited. Non-alcoholic fatty liver disease (NAFLD) affects approximately one in three UK adults and requires evidence-based management. This article examines the scientific evidence behind beetroot's purported liver benefits, explores what research actually shows, and clarifies how beetroot fits within a comprehensive approach to managing fatty liver disease according to UK clinical guidance.

Understanding Fatty Liver Disease and Its Causes

Fatty liver disease, medically termed hepatic steatosis, occurs when excess fat accumulates in liver cells. This condition affects approximately one in three adults in the UK and exists in two main forms: non-alcoholic fatty liver disease (NAFLD) and alcohol-related liver disease (ARLD). NAFLD is increasingly common and closely linked to metabolic health, whilst ARLD results from excessive alcohol consumption over time.

The liver normally contains small amounts of fat, but when fat comprises 5% or more of hepatocytes (liver cells) on histology or quantitative imaging such as MRI-PDFF, it becomes pathological. In its early stages, simple steatosis typically causes no symptoms and may be discovered incidentally during imaging for other conditions. Importantly, liver function tests (LFTs) are often normal in people with NAFLD. However, without intervention, fatty liver can progress to non-alcoholic steatohepatitis (NASH), characterised by inflammation and liver cell damage, and potentially advance to fibrosis, cirrhosis, or hepatocellular carcinoma.

Key risk factors for NAFLD include:

• Obesity, particularly central adiposity

• Type 2 diabetes mellitus

• Insulin resistance and metabolic syndrome

• Dyslipidaemia (elevated triglycerides, low HDL cholesterol)

• Sedentary lifestyle and poor dietary habits

The pathophysiology involves complex metabolic dysfunction best described by the 'multiple-hit' model. Insulin resistance promotes increased fatty acid delivery to the liver, impaired fat oxidation, and enhanced lipogenesis. Concurrently, oxidative stress, gut-derived endotoxins, genetic factors, and inflammatory pathways interact to drive disease progression from simple steatosis to NASH and fibrosis.

According to NICE guidance (NG49), diagnosis involves evidence of hepatic steatosis (typically on ultrasound or other imaging), exclusion of other liver diseases (viral hepatitis, autoimmune hepatitis, haemochromatosis, Wilson's disease, thyroid disorders, and drug-induced liver injury), and assessment of fibrosis risk. In UK primary care, fibrosis risk stratification uses:

• FIB-4 score – calculated from age, liver enzymes, and platelet count. In adults under 65 years, FIB-4 <1.3 indicates low risk and >2.67 high risk; in those aged 65 and over, <2.0 indicates low risk

• NAFLD Fibrosis Score – an alternative validated tool

• Enhanced Liver Fibrosis (ELF) blood test – recommended by NICE for further assessment; ELF ≥10.51 suggests advanced fibrosis and warrants specialist referral

• Transient elastography (FibroScan) – where available, measures liver stiffness to assess fibrosis

Adults with NAFLD and a negative ELF test should be reassessed every three years. Patients with high-risk scores or uncertain results should be referred to hepatology. Early detection and lifestyle modification remain the cornerstone of management, as there is currently no MHRA-licensed pharmacological treatment specifically for NAFLD in the UK.

Beetroot's Nutritional Properties and Liver Health Benefits

Beetroot (Beta vulgaris) is a nutrient-dense root vegetable that has garnered scientific interest for its potential health properties. This vibrant vegetable contains a unique combination of bioactive compounds, though their clinical significance for liver disease requires careful evaluation.

Beetroot is particularly rich in:

• Betalains – pigmented antioxidants (betacyanins and betaxanthins) with anti-inflammatory properties in laboratory studies

• Dietary nitrates – converted to nitric oxide, supporting vascular function

• Betaine (trimethylglycine) – a methyl donor involved in liver metabolism

• Fibre – supporting digestive health and metabolic regulation

• Folate, manganese, and potassium – essential micronutrients

Betaine deserves particular attention in the context of liver health. This compound participates in the methionine cycle, facilitating methylation reactions crucial for lipid metabolism and reducing homocysteine levels. Preclinical studies suggest betaine may help prevent hepatic lipid accumulation by modulating fat metabolism and reducing oxidative stress within hepatocytes, though these findings have not been consistently replicated in human trials.

The betalain pigments in beetroot demonstrate antioxidant capacity in laboratory settings. Whilst oxidative damage is a key factor in the progression from simple steatosis to inflammatory NASH, whether dietary betalains reach sufficient concentrations in human liver tissue to exert clinically meaningful effects remains unproven. Claims that beetroot supports the liver's 'detoxification' processes by enhancing phase II enzyme activity are theoretical and lack robust human evidence.

Dietary nitrates in beetroot are converted to nitric oxide, which improves endothelial function and blood flow. Whilst this primarily benefits cardiovascular health, any effect on hepatic microcirculation in the context of fatty liver disease is speculative. Important safety note: concentrated beetroot juice and nitrate supplements can lower blood pressure. People taking antihypertensive medications or those with low blood pressure should monitor their response and discuss use with their GP or pharmacist.

It is important to note that whilst beetroot contains these beneficial compounds, their presence does not automatically translate to therapeutic efficacy for fatty liver disease. The concentration, bioavailability, and clinical significance of these nutrients when consumed as whole food require rigorous evaluation through well-designed human trials.

Can Beetroot Reverse Fatty Liver? What the Evidence Shows

The claim that beetroot can 'reverse' fatty liver disease requires careful scrutiny of available evidence. Whilst beetroot contains compounds with theoretical health properties, there is no established clinical evidence that beetroot consumption reverses fatty liver disease in humans. The current evidence base consists primarily of animal studies and limited human research, which cannot support definitive therapeutic claims.

Animal studies have shown promising results. Research in rodent models of NAFLD has demonstrated that beetroot extract or betaine supplementation may reduce hepatic steatosis, decrease liver enzyme elevations, and improve markers of oxidative stress. These studies suggest potential mechanisms including enhanced fat oxidation, reduced lipogenesis, and anti-inflammatory effects. However, animal models do not reliably predict human responses, particularly given differences in metabolism, dosing, and disease complexity.

Human evidence remains sparse and inconclusive. A few small studies have examined betaine supplementation (not whole beetroot) in patients with NAFLD, with mixed results. Some trials reported modest improvements in liver enzymes or hepatic fat content on imaging, whilst others found no significant benefit. Systematic reviews have concluded that the evidence is insufficient to recommend betaine or beetroot-derived supplements for NAFLD treatment. These studies typically used isolated betaine supplements at doses far exceeding what could be obtained from dietary beetroot consumption alone. Methodological limitations, including small sample sizes, short duration, and lack of standardisation, prevent firm conclusions.

Critical considerations include:

• No large-scale randomised controlled trials have evaluated beetroot specifically for NAFLD

• Existing studies often examine isolated compounds rather than whole beetroot

• 'Reversal' implies complete resolution, which has not been demonstrated with beetroot

• Individual responses likely vary based on disease severity, genetics, and overall diet

• Histological resolution of NASH and regression of fibrosis are most strongly associated with sustained weight loss of 7–10% or more of body weight, not individual dietary components

According to NICE (NG49) and British Society of Gastroenterology guidance, lifestyle modification—particularly weight loss through caloric restriction and increased physical activity—remains the only evidence-based first-line treatment for NAFLD. Whilst beetroot is undoubtedly a nutritious food that can form part of a healthy diet, it should not be viewed as a standalone treatment or 'cure' for fatty liver disease. Patients with diagnosed NAFLD should not rely on beetroot consumption as a substitute for evidence-based lifestyle modifications or medical management recommended by their healthcare team.

How to Use Beetroot as Part of a Liver-Healthy Diet

Although beetroot alone cannot reverse fatty liver disease, it can be incorporated as part of a comprehensive dietary approach to support liver health and overall metabolic wellbeing. The key is viewing beetroot as one component of a balanced, nutrient-rich eating pattern rather than a therapeutic intervention.

Practical ways to include beetroot in your diet:

• Fresh beetroot – roasted, boiled, or grated raw into salads (approximately 100–150g serving provides beneficial nutrients without excessive calories)

• Beetroot juice – small amounts (150–200ml) can be consumed, though whole beetroot is preferable due to fibre content

• Pickled beetroot – convenient but check labels for added sugar and sodium

• Beetroot leaves – the greens are edible and nutrient-dense, suitable for cooking like spinach

When incorporating beetroot, consider these evidence-based principles for liver health. Beetroot should complement, not replace, other vegetables in a Mediterranean-style dietary pattern, which the British Society of Gastroenterology, EASL (European Association for the Study of the Liver), and NHS recognise as beneficial for metabolic and liver health. Aim for variety, including leafy greens, cruciferous vegetables, and other colourful produce that provide diverse phytonutrients and antioxidants.

Important considerations:

• Beetroot contains natural sugars (approximately 7g per 100g), so portion control matters, particularly for individuals with diabetes or insulin resistance

• Beetroot juice is more concentrated in sugars and lacks fibre—whole beetroot is nutritionally superior

• Concentrated beetroot juice and nitrate supplements can lower blood pressure; people taking antihypertensive medications or those with low blood pressure should monitor their response and discuss use with their GP or pharmacist

• Some individuals may experience beeturia (red-coloured urine or stools) after consumption, which is harmless

• Beetroot is high in oxalates; those with a history of kidney stones should moderate intake and consult their GP. See the NHS kidney stones prevention page for further guidance

• Beetroot greens are high in vitamin K; people taking warfarin should maintain consistent intake and discuss any dietary changes with their anticoagulation clinic or GP

For optimal liver health, beetroot should be part of a diet that emphasises whole foods, limits processed foods, refined carbohydrates, and saturated fats, and maintains appropriate caloric intake for weight management. No single food, including beetroot, can compensate for an otherwise poor dietary pattern. Patients with diagnosed fatty liver disease should discuss dietary changes with their GP or seek referral to a registered dietitian for personalised nutritional guidance aligned with their specific health needs and comorbidities.

Other Dietary and Lifestyle Changes for Fatty Liver

Managing fatty liver disease effectively requires a comprehensive approach centred on evidence-based lifestyle modifications. According to NICE (NG49) and British Society of Gastroenterology guidelines, weight loss and dietary improvement represent first-line interventions for NAFLD, with stronger evidence than any single food or supplement.

Dietary modifications with robust evidence include:

• Caloric restriction for weight loss – even modest weight reduction of 5–10% of body weight can significantly reduce hepatic fat and improve liver enzymes; weight loss of 7–10% or more is associated with histological resolution of NASH and regression of fibrosis

• Mediterranean dietary pattern – emphasising vegetables, fruits, whole grains, legumes, nuts, olive oil, and fish whilst limiting red meat and processed foods

• Reduced refined carbohydrates and added sugars – particularly fructose-containing beverages and foods, which directly contribute to hepatic lipogenesis

• Increased dietary fibre – supporting metabolic health and promoting satiety

• Moderate coffee consumption – observational evidence suggests 2–3 cups daily may have hepatoprotective effects

Physical activity is equally crucial. The UK Chief Medical Officers' Physical Activity Guidelines recommend at least 150 minutes of moderate-intensity aerobic activity weekly (such as brisk walking or cycling), combined with muscle-strengthening activities on two or more days per week. Exercise improves insulin sensitivity, promotes fat oxidation, and can reduce hepatic steatosis independent of weight loss. Both structured exercise programmes and increased daily activity (walking, cycling, gardening) contribute beneficially.

Additional lifestyle factors include:

• Alcohol abstinence or strict limitation – UK guidance recommends keeping alcohol consumption to 14 units or fewer per week, spread over three or more days with several drink-free days. Even in NAFLD, alcohol can accelerate disease progression; some patients may be advised to abstain completely

• Smoking cessation – smoking is associated with increased fibrosis risk

• Optimising management of comorbidities – diabetes control, lipid management, and blood pressure regulation. Statins are safe in NAFLD and should be used for cardiovascular risk reduction as indicated; do not stop statins without medical advice

• Adequate sleep – poor sleep quality and obstructive sleep apnoea are linked to NAFLD severity

UK fibrosis risk assessment and monitoring: If you have been diagnosed with NAFLD, your GP will assess your risk of advanced fibrosis using tools such as the FIB-4 score (age-adjusted thresholds: in adults under 65, <1.3 is low risk and >2.67 is high risk; in those 65 and over, <2.0 is low risk). Further assessment may include the Enhanced Liver Fibrosis (ELF) blood test; an ELF score ≥10.51 suggests advanced fibrosis and warrants referral to a liver specialist. Transient elastography (FibroScan) may also be used where available. Adults with NAFLD and a negative ELF test should be reassessed every three years.

When to contact your GP:

• Persistent fatigue, abdominal discomfort, or unexplained weight loss

• Known fatty liver with worsening symptoms

• Concerns about alcohol consumption

• Difficulty implementing lifestyle changes independently

Seek urgent or same-day medical attention if you experience:

• Yellowing of the skin or eyes (jaundice)

• Increasing abdominal swelling or distension (ascites)

• Confusion, drowsiness, or altered mental state

• Vomiting blood or passing black, tarry stools

• Severe right upper abdominal pain with fever

• Marked itching (pruritus) without rash

Patients with NAFLD should have regular monitoring, typically including liver function tests and assessment of metabolic parameters. Those with advanced fibrosis, NASH, or uncertain diagnosis require specialist hepatology referral. Importantly, there are currently no MHRA-licensed medications specifically for NAFLD, though several are under investigation. Lifestyle modification remains the evidence-based foundation of treatment, and sustainable changes yield the most significant long-term benefits for liver health and overall wellbeing.

If you experience any suspected side effects from medicines or supplements, you can report them via the MHRA Yellow Card scheme at www.gov.uk/yellowcard or by searching for 'Yellow Card' in the Google Play or Apple App Store.

Frequently Asked Questions